PT - JOURNAL ARTICLE AU - Spencer Woody AU - Mauricio Tec AU - Maytal Dahan AU - Kelly Gaither AU - Spencer J. Fox AU - Lauren Ancel Meyers AU - James Scott TI - Projections for first-wave COVID-19 deaths across the US using social-distancing measures derived from mobile phones AID - 10.1101/2020.04.16.20068163 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.16.20068163 4099 - http://medrxiv.org/content/early/2020/04/22/2020.04.16.20068163.short 4100 - http://medrxiv.org/content/early/2020/04/22/2020.04.16.20068163.full AB - On March 26, 2020, the Institute for Health Metrics and Evaluation (IHME) at the University of Washington released a website that forecasts coronavirus disease (COVID-19) healthcare demand and mortality for all states in the United States. In light of the popular appeal of the IHME model and considerable scrutiny from the scientific community, we have developed an alternative curve-fitting method for forecasting COVID-19 mortality throughout the US. Our model is similar in spirit to the IHME model, but different in two important details. First, for each US state, we use local data from mobile-phone GPS traces made available by SafeGraph to quantify the changing impact of social-distancing measures on “flattening the curve.” Second, we reformulated the approach in a generalized linear model framework to correct a statistical flaw that leads to the underestimation of uncertainty in the IHME forecasts. The incorporation of real-time geolocation data and several key modifications yields projections that differ noticeably from the IHME model, especially regarding uncertainty when projecting COVID-19 deaths several weeks into the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially funded by grants from the National Science Foundation, the National Institutes of Health, and by a gift from Tito’s Handmade Vodka to the UT COVID-19 Modeling Consortium.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData on COVID-19 deaths were provided by the New York Times and are publicly available: https://github.com/nytimes/covid-19-data/ Data on social-distancing metrics were provided under a Data Use Agreement by SafeGraph and are available by contacting SafeGraph directly: https://www.safegraph.com/dashboard/covid19-shelter-in-place https://www.safegraph.com